DiabetesRes Clin Pr:糖尿病或不影响我国腹透患者生存率

2013-06-07 佚名 中华医学会糖尿病学会分会

  中山大学第一附属医院肾内科余学清教授等公布的一项为期5年的临床队列研究表明,在我国接受持续性不卧床腹膜透析(CAPD)的患者中,糖尿病并不显著影响生存率。对于接受CAPD的糖尿病患者,CAPD治疗时高龄、合并心血管疾病、血糖水平高、贫血和低白蛋白血症是影响生存率的因素。(Diabetes Res Clin Pract. 2013年4月22日在线版)  

  中山大学第一附属医院肾内科余学清教授等公布的一项为期5年的临床队列研究表明,在我国接受持续性不卧床腹膜透析(CAPD)的患者中,糖尿病并不显著影响生存率。对于接受CAPD的糖尿病患者,CAPD治疗时高龄、合并心血管疾病、血糖水平高、贫血和低白蛋白血症是影响生存率的因素。(Diabetes Res Clin Pract. 2013年4月22日在线版)

  该纵向队列研究入选809例接受CAPD的肾病患者,23.4%合并糖尿病。糖尿病患者和非糖尿病患者的死亡审查技术生存率无显著差异(P=0.271)。然而,糖尿病患者1、2、3、5年生存率依次为90%、72%、63%和36%,非糖尿病组则依次为95%、92%、87%和73%(P=0.000)。在启动CAPD时,合并心血管疾病、高龄、糖化血红蛋白水平较高、低白蛋白血症和血红蛋白水平降低均是糖尿病患者死亡的独立预测因素。

Clinical outcome and risk factors for mortality in Chinese patients with diabetes on peritoneal dialysis: A 5-year clinical cohort study
Aims
We evaluated clinical outcome and risk factors affecting survival in patients with diabetes on continuous ambulatory peritoneal dialysis (CAPD) in Southern China.
Methods
This longitudinal cohort study enrolled all incident patients who used CAPD as their first renal replacement therapy modality in our center from January 2006 to December 2009 and who were followed until December 2011. Clinical outcomes were compared and risk factors for mortality in patients with diabetes were analyzed.
Results
Of 809 incident CAPD patients, 189 (23.4%) had diabetes. Death-censored technique survival showed no significant difference between patients with and without diabetes (p=0.271). The 1-, 2-, 3- and 5-year patient survival rates were 90%, 72%, 63% and 36% in patients with diabetes and 95%, 92%, 87% and 73% in patients without diabetes, respectively (p=0.000). Presence of cardiovascular disease (CVD) [hazard ratio (HR) 2.130, 95% confidence interval (CI) 1.199–3.786, p=0.010], advanced age (HR 1.042, 95% CI 1.008–1.078, p=0.014), higher glycated hemoglobin (HR 1.309, 95% CI 1.045–1.640, p=0.019), lower hemoglobin (HR 0.978, 95% CI 0.964–0.992, p=0.003) and lower serum albumin (HR 0.924, 95% CI 0.876–0.976, p=0.004) at the initiation of CAPD were independent risk factors of mortality in CAPD patients with diabetes.
Conclusions
Technique survival in CAPD patients with diabetes was similar to those without diabetes. Although patients with diabetes had higher risk of mortality, the patient survival in our study seems to be improved compared with most other reports. Older age, presence of CVD, hyperglycemia, anemia and hypoalbuminemia at the commencement of CAPD affected survival in patients with diabetes.    

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1759301, encodeId=7d161e59301b2, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Thu Oct 24 02:02:00 CST 2013, time=2013-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636689, encodeId=2734163668976, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Feb 19 09:02:00 CST 2014, time=2014-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901105, encodeId=2cb3190110579, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Fri Aug 30 06:02:00 CST 2013, time=2013-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932472, encodeId=bb6419324e20f, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Wed Dec 18 05:02:00 CST 2013, time=2013-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256465, encodeId=de1e1256465a6, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Sun Jun 09 01:02:00 CST 2013, time=2013-06-09, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1759301, encodeId=7d161e59301b2, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Thu Oct 24 02:02:00 CST 2013, time=2013-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636689, encodeId=2734163668976, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Feb 19 09:02:00 CST 2014, time=2014-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901105, encodeId=2cb3190110579, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Fri Aug 30 06:02:00 CST 2013, time=2013-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932472, encodeId=bb6419324e20f, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Wed Dec 18 05:02:00 CST 2013, time=2013-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256465, encodeId=de1e1256465a6, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Sun Jun 09 01:02:00 CST 2013, time=2013-06-09, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1759301, encodeId=7d161e59301b2, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Thu Oct 24 02:02:00 CST 2013, time=2013-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636689, encodeId=2734163668976, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Feb 19 09:02:00 CST 2014, time=2014-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901105, encodeId=2cb3190110579, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Fri Aug 30 06:02:00 CST 2013, time=2013-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932472, encodeId=bb6419324e20f, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Wed Dec 18 05:02:00 CST 2013, time=2013-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256465, encodeId=de1e1256465a6, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Sun Jun 09 01:02:00 CST 2013, time=2013-06-09, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1759301, encodeId=7d161e59301b2, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Thu Oct 24 02:02:00 CST 2013, time=2013-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636689, encodeId=2734163668976, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Feb 19 09:02:00 CST 2014, time=2014-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901105, encodeId=2cb3190110579, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Fri Aug 30 06:02:00 CST 2013, time=2013-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932472, encodeId=bb6419324e20f, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Wed Dec 18 05:02:00 CST 2013, time=2013-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256465, encodeId=de1e1256465a6, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Sun Jun 09 01:02:00 CST 2013, time=2013-06-09, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1759301, encodeId=7d161e59301b2, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Thu Oct 24 02:02:00 CST 2013, time=2013-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636689, encodeId=2734163668976, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Feb 19 09:02:00 CST 2014, time=2014-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901105, encodeId=2cb3190110579, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Fri Aug 30 06:02:00 CST 2013, time=2013-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932472, encodeId=bb6419324e20f, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Wed Dec 18 05:02:00 CST 2013, time=2013-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256465, encodeId=de1e1256465a6, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Sun Jun 09 01:02:00 CST 2013, time=2013-06-09, status=1, ipAttribution=)]

相关资讯

Diabetologia:哈尔滨医科大学孙长颢发现补充组氨酸可改善胰岛素抵抗

炎症反应和氧化应激的增加与胰岛素抵抗(IR)和代谢紊乱有关。在肥胖女性,血清组氨酸水平降低,并与炎症反应和氧化应激成负相关。为了评估在伴有代谢综合征(Mets)的肥胖女性,组氨酸补充治疗对IR、炎症反应、氧化应激和代谢紊乱的功效,来自哈尔滨医科大学公共卫生学院的孙长颢教授及其团队进行了一项研究(Histidinesupplementation improves insulin resistance

Stroke:糖尿病、入院血糖较高与卒中溶栓后转归较差相关

糖尿病及入院血糖对卒中溶栓后转归是否存在不利作用尚不清楚。为此,法国巴黎Bichat大学医院神经内科与卒中中心的Jean-PhilippeDesilles博士等进行了一项研究,研究结果在线发表在2013年5月23日的Stroke杂志上。研究结果显示:入院血糖高及糖尿病史与溶栓后临床转归差相关。入院血糖可以作为脑梗死严重程度的替代标志物。 该研究是一项患者注册及系统回归分析。研究人员分析来自患者注

JCEM:T2DM胰岛素治疗增加糖尿病相关并发症

胰岛素在2型糖尿病(T2DM)治疗中的安全性最近遭受质疑。为了描述2型糖尿病患者降血糖治疗相关不良事件的风险。来自英国加的夫药物研究中心Craig J Currie教授及其团队进行了一项研究,该研究发现,在2型糖尿病患者,外源性胰岛素治疗与糖尿病相关并发症、癌症和全因死亡率风险增加有关。该研究结果在线发表在2013年2月的《临床内分泌代谢杂志》(The journal of clinical en

ASCO 2013:肝细胞癌临床研究结果大放送

整体而言,ASCO年会对肝细胞癌的关注还是不多;让人无语的是,尽管中国人发病最多,但在ASCO 2013的肝癌摘要上却很少能见到中国人的身影。本文从中筛选出了其中肝细胞癌相关的研究,做简单介绍。因为晚期肝癌已经有了索拉非尼这个标准治疗方式,新发展的局部或全身治疗要么是跟索拉非尼联用的一线治疗,要么就是作为索拉非尼的二线治疗。 一线治疗:使用阿霉素洗脱微球的TACE(DEB-TACE)+索拉非尼的

Diabetes Res Clin Pr:米格列醇/米格列奈联合比单药治疗更有效

在日本2型糖尿病患者,为了评估米格列醇与米格列奈单独或联合使用对代谢谱和肠促胰岛素分泌的功效。来自日本川崎医科大学的Mitsuru Hashiramoto教授及其团队进行了一项研究,该研究发现米格列醇/米格列奈联合使用比单药治疗在减少餐后血糖波动和同时减少额外胰岛素分泌,改善血糖控制方面更有效。该研究同时证明米格列醇和米格列奈对肠促胰岛素分泌的影响有显著差异。该研究结果在线发表在5月24日的《糖尿

JAMA Intern Med:吃素比吃肉更长寿

研究发现,素食者死于心脏病的可能性比肉食者低19%。据《美国医学会杂志?内科学》(JAMA Internal Medicine)周一发表的一项研究显示,素食者比肉食者更长寿。 研究作者对73,308名基督复临安息日会(Seventh-day Adventist Church)的成员进行了为期近六年的跟踪调查。该教会主张素食,不过并非所有的信徒都遵守这一教义。研究人员调查研究对象所吃食物的种类,然